Cancer Research Center.
Gratis bloggen bei
Increased urinary CCL2: Cr ratio in 6 months later the renal allograft loss.
Early non-invasive markers, identification of risk patients renal allograft loss work stratified patients may more monitoring or treatment. Is a CCR2 CCL2 chemokine receptor protein, this is a chemoattractant to monocytes/macrophages, T cells and natural killer cells. We've demonstrates in a multicenter cohort, urine CCL2 in 6 months is an independent predictor of IFTA in 24 months. The goal of this study was to determine the early can predict urine CCL2 graft loss in an independent patient population.
A prospective observational cohort study on the adult kidney transplant Manitoba program (n = 231) from 1997 to 2008. Six months of urine CCL2 measured the ELISA, remove urine creatinine, and long-term transplantation results.
Urine CCL2: Cr in 6 months significant related death review graft loss (odds ratio, 2.42; 95% CI, 1.54 to 3.82, P < 0.0001). In multivariate analysis, urine CCL2: Cr in 6 months is still an independent predict death review graft loss (odds ratio, 2.20; 95% CI, 1.18 to 4.10, P = 0.01) after the adjustment before transplantation/DE novo specific antibodies and delayed graft function. Early transplantation (6 months or less) multivariate model the CCL2, the recipient's age, and delayed graft function recovery produced a 0.87 AUC predict death review graft loss. A cut-off value of urine CCL2: Cr 34.8 ng/and a strong positive predictive value is 0.96.
The study confirmed in a separate prospective cohort, early urine CCL2 in 6 months is a non-invasive, independent indicate late renal allograft loss.
bisher 0 Kommentar(e)